Drug survival in the treatment of generalized pustular psoriasis: A retrospective multicenter study.
GPP
IL-12/23
IL-17
TNF-alpha
Zumbusch
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
revised:
10
01
2021
received:
27
10
2020
accepted:
20
01
2021
pubmed:
27
1
2021
medline:
26
5
2021
entrez:
26
1
2021
Statut:
ppublish
Résumé
Generalized pustular psoriasis (GPP) is a rare, potentially life-threatening inflammatory skin disease. Our aim was to assess patient and disease characteristics and analyze drug survival rates in the treatment of GPP in a real-life setting. In this retrospective study, 201 treatment series of 86 patients with GPP treated at five University Medical Centers were analyzed. Overall, excellent response was reached in 41.3% of all treatment courses, partial response in 31.4%, and nonresponse in 27.3%. Biological treatment was significantly more effective than non-biological therapies (excellent response: 47.4% vs 35.9%; P = .02). Overall, the median drug survival was 14.0 months (biologicals: 36.0 months vs nonbiologicals: 6.0 months; P < .001). The crude probability of survival was highest for secukinumab (hazard ratio [HR] of drug discontinuation compared with acitretin: 0.22), followed by ixekizumab and ustekinumab (HR: 0.38 each), adalimumab (HR: 0.59), etanercept (HR: 0.62), infliximab (HR: 0.69), cyclosporine (HR: 1.00), acitretin (reference for HR), fumaric acid esters (HR: 1.06), methotrexate (HR: 1.26), and apremilast (HR: 3.44); no drug discontinuation with guselkumab. Our results reveal high efficacy and drug survival, particularly for IL-17 and IL-(12)/23 antagonists. Thus, these biologics may be considered early in the therapeutic algorithm of GPP.
Substances chimiques
Pharmaceutical Preparations
0
Interleukin-12
187348-17-0
Ustekinumab
FU77B4U5Z0
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14814Subventions
Organisme : WOA Institution: GEORG-AUGUST-UNIVERSITAET GOTTINGEN Blended DEAL: ProjektDEAL
Informations de copyright
© 2021 The Authors. Dermatologic Therapy published by Wiley Periodicals LLC.
Références
Hoegler KM, John AM, Handler MZ, Schwartz RA. Generalized pustular psoriasis: a review and update on treatment. J Eur Acad Dermatol Venereol. 2018;32(10):1645-1651.
Navarini AA, Burden AD, Capon F, et al. European consensus statement on phenotypes of pustular psoriasis. J Eur Acad Dermatol Venereol. 2017;31(11):1792-1799.
Umezawa Y, Ozawa A, Kawasima T, et al. Therapeutic guidelines for the treatment of generalized pustular psoriasis (GPP) based on a proposed classification of disease severity. Arch Dermatol Res. 2003;295(suppl 1):S43-S54.
Viguier M, Allez M, Zagdanski AM, et al. High frequency of cholestasis in generalized pustular psoriasis: evidence for neutrophilic involvement of the biliary tract. Hepatology. 2004;40(2):452-458.
Kawana S, Nishiyama S. Pustular psoriasis and aseptic purulent arthritis: possible role of leukotrienes B4 and C4 in a flare of synovitis. Dermatology. 1995;190(1):35-38.
Sadeh JS, Rudikoff D, Gordon ML, Bowden J, Goldman BD, Lebwohl M. Pustular and erythrodermic psoriasis complicated by acute respiratory distress syndrome. Arch Dermatol. 1997;133(6):747-750.
Benomar S, Belgnaoui F, Meziane M, Senouci K, Hassam B. Extra-cutaneous systemic manifestations in generalized pustular psoriasis. Rev Med Interne. 2010;31(7):e16-e18.
Weisenseel P, Wilsmann-Theis D, Kahl C, Reich K, Mossner R. Pustular psoriasis. Hautarzt. 2016;67(6):445-453.
Robinson A, Van Voorhees AS, Hsu S, et al. Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2012;67(2):279-288.
Fujita H, Terui T, Hayama K, et al. Japanese guidelines for the management and treatment of generalized pustular psoriasis: the new pathogenesis and treatment of GPP. J Dermatol. 2018;45(11):1235-1270.
Boehner A, Navarini AA, Eyerich K. Generalized pustular psoriasis-a model disease for specific targeted immunotherapy, systematic review. Exp Dermatol. 2018;27(10):1067-1077.
van den Reek J, Kievit W, Gniadecki R, et al. Drug survival studies in dermatology:principles, purposes, and pitfalls. J Invest Dermatol. 2015;135(7):1-5.
Costanzo A, Malara G, Pelucchi C, et al. Effectiveness end points in real-World studies on biological therapies in psoriasis: systematic review with focus on drug survival. Dermatology. 2018;234(1-2):1-12.
Arnold T, Schaarschmidt ML, Herr R, Fischer JE, Goerdt S, Peitsch WK. Drug survival rates and reasons for drug discontinuation in psoriasis. J Dtsch Dermatol Ges. 2016;14(11):1089-1099.
Egeberg A, Ottosen MB, Gniadecki R, et al. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol. 2018;178(2):509-519.
Iskandar IYK, Warren RB, Lunt M, et al. Differential drug survival of second-line biologic therapies in patients with psoriasis: observational cohort study from the British Association of Dermatologists biologic interventions register (BADBIR). J Invest Dermatol. 2018;138(4):775-784.
Lin PT, Wang SH, Chi CC. Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence. Sci Rep. 2018;8(1):16068.
Mason KJ, Williams S, Yiu ZZN, et al. Persistence and effectiveness of nonbiologic systemic therapies for moderate-to-severe psoriasis in adults: a systematic review. Br J Dermatol. 2019;181(2):256-264.
No DJ, Inkeles MS, Amin M, Wu JJ. Drug survival of biologic treatments in psoriasis: a systematic review. J Dermatolog Treat. 2018;29(5):460-466.
Vilarrasa E, Notario J, Bordas X, Lopez-Ferrer A, Gich IJ, Puig L. ORBIT (outcome and retention rate of biologic treatments for psoriasis): a retrospective observational study on biologic drug survival in daily practice. J Am Acad Dermatol. 2016;74(6):1066-1072.
Kromer C, Wilsmann-Theis D, Gerdes S, et al. Drug survival and reasons for drug discontinuation in palmoplantar pustulosis: a retrospective multicenter study. J Dtsch Dermatol Ges. 2019;17(5):503-516.
Kishimoto M, Komine M, Kamiya K, Sugai J, Mieno M, Ohtsuki M. Drug survival of biologic agents for psoriatic patients in a real-world setting in Japan. J Dermatol. 2020;47(1):33-40.
Huffmeier U, Watzold M, Mohr J, Schon MP, Mossner R. Successful therapy with anakinra in a patient with generalized pustular psoriasis carrying IL36RN mutations. Br J Dermatol. 2014;170(1):202-204.
World Medical A. World Medical association declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-2194.
Baker H, Ryan TJ. Generalized pustular psoriasis. A clinical and epidemiological study of 104 cases. Br J Dermatol. 1968;80(12):771-793.
Twelves S, Mostafa A, Dand N, et al. Clinical and genetic differences between pustular psoriasis subtypes. J Allergy Clin Immunol. 2019;143(3):1021-1026.
Jin H, Cho HH, Kim WJ, et al. Clinical features and course of generalized pustular psoriasis in Korea. J Dermatol. 2015;42(7):674-678.
Kharawala S, Golembesky AK, Bohn RL, Esser D. The clinical, humanistic, and economic burden of generalized pustular psoriasis: a structured review. Expert Rev Clin Immunol. 2020;16(3):239-252.
Choon SE, Lai NM, Mohammad NA, Nanu NM, Tey KE, Chew SF. Clinical profile, morbidity, and outcome of adult-onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in Johor, Malaysia. Int J Dermatol. 2014;53(6):676-684.
Wilsmann-Theis D, Jacobi A, Frambach Y, et al. Palmoplantar pustulosis - a cross-sectional analysis in Germany. Dermatol Online J. 2017;23(4).
Takeichi T, Akiyama M. Generalized Pustular psoriasis: clinical management and update on autoinflammatory aspects. Am J Clin Dermatol. 2020;21(2):227-236.
Kromer C, Loewe E, Schaarschmidt ML, et al. Treatment of acrodermatitis continua of Hallopeau: a case series of 39 patients. J Dermatol. 2020;47(9):989-997.
Sanchez IM, Sorenson E, Levin E, Liao W. The efficacy of biologic therapy for the management of palmoplantar psoriasis and palmoplantar pustulosis: a systematic review. Dermatol Ther (Heidelb). 2017;7(4):425-446.
Yiu ZZN, Mason KJ, Hampton PJ, et al. Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). Br J Dermatol. 2020;183(2):294-302.
Ellis CN, Fradin MS, Messana JM, et al. Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. N Engl J Med. 1991;324(5):277-284.
Nast A, Amelunxen L, Augustin M, et al. S3 guideline for the treatment of psoriasis vulgaris, update-short version part 1-systemic treatment. J Dtsch Dermatol Ges. 2018;16(5):645-669.
Elewski BE. Infliximab for the treatment of severe pustular psoriasis. J Am Acad Dermatol. 2002;47(5):796-797.
Imafuku S, Honma M, Okubo Y, et al. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: a 52-week analysis from phase III open-label multicenter Japanese study. J Dermatol. 2016;43(9):1011-1017.
Morita A, Yamazaki F, Matsuyama T, et al. Adalimumab treatment in Japanese patients with generalized pustular psoriasis: results of an open-label phase 3 study. J Dermatol. 2018;45(12):1371-1380.
Saeki H, Nakagawa H, Ishii T, et al. Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis. J Eur Acad Dermatol Venereol. 2015;29(6):1148-1155.
Saeki H, Nakagawa H, Nakajo K, et al. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52-week, open-label, phase 3 study (UNCOVER-J). J Dermatol. 2017;44(4):355-362.
Storan ER, O'Gorman SM, Markham T. Generalized pustular psoriasis treated with ustekinumab. Clin Exp Dermatol. 2016;41(6):689-690.
Yamasaki K, Nakagawa H, Kubo Y, Ootaki K. Japanese Brodalumab study G. efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study. Br J Dermatol. 2017;176(3):741-751.
Wilsmann-Theis D, Schnell LM, Ralser-Isselstein V, et al. Successful treatment with interleukin-17A antagonists of generalized pustular psoriasis in patients without IL36RN mutations. J Dermatol. 2018;45(7):850-854.
Gooderham MJ, Van Voorhees AS, Lebwohl MG. An update on generalized pustular psoriasis. Expert Rev Clin Immunol. 2019;15(9):907-919.